CIK 0001472012 · Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770694340
- Phone
- 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 56 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-02 | Rosett Max Chief Financial Officer | Option exercise 10b5-1 | +31,848 | $1.05 | $33K | 79,324 |
| 2026-04-02 | Rosett Max Chief Financial Officer | Option exercise 10b5-1 | +39,713 | $1.35 | $54K | 119,037 |
| 2026-04-02 | Rosett Max Chief Financial Officer | Sale 10b5-1 | −63,656 | $21.91 | $1.4M | 55,381 |
| 2026-04-02 | Rosett Max Chief Financial Officer | Sale 10b5-1 | −1,344 | $22.48 | $30K | 54,037 |
| 2026-04-02 | Rosett Max Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −31,848 | 60,000 | ||
| 2026-04-02 | Rosett Max Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −39,713 | 0 | ||
| 2026-04-02 | Higgins Jack Chief Scientific Officer | Sale 10b5-1 | −9,438 | $21.64 | $204K | 22,000 |
| 2026-03-30 | Higgins Jack Chief Scientific Officer | Gift | −6,291 | 31,438 | ||
| 2026-03-27 | SIEGALL CLAY B President and CEO | Purchase | +25,450 | $19.67 | $501K | 690,704 |
| 2026-03-23 | WAGENHEIM PHILIP Director | Sale | −28,200 | $20.65 | $582K | 341,147 |
| 2026-03-20 | WAGENHEIM PHILIP Director | Sale | −36,800 | $20.47 | $753K | 369,347 |
| 2026-03-11 | BIENAIME JEAN JACQUES Director | Purchase | +1,000 | $21.55 | $22K | 38,415 |
| 2026-03-10 | BIENAIME JEAN JACQUES Director | Purchase | +1,000 | $22.12 | $22K | 37,415 |
| 2025-12-30 | SIEGALL CLAY B President and CEO | Purchase | +4,729 | $21.15 | $100K | 665,254 |
| 2025-12-22 | Barchas Isaac Director | Sale 10b5-1 | −371,949 | $21.72 | $8.1M | 2,042,432 |
| 2025-12-22 | Barchas Isaac Director | Sale 10b5-1 | −11,251 | $22.34 | $251K | 2,031,181 |
| 2025-12-19 | Tsai Philip Chief Technical Officer | Purchase | +10,000 | $20.49 | $205K | 43,300 |
| 2025-12-19 | Higgins Jack Chief Scientific Officer | Gift | −1,000 | 39,729 | ||
| 2025-12-19 | Higgins Jack Chief Scientific Officer | Gift | +1,000 | 1,000 | ||
| 2025-12-19 | Higgins Jack Chief Scientific Officer | Gift | −1,000 | 38,729 |
Page 4 of 8 · 159 trades